Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical has announced that, together with its partner Merck KGaA, it has decided to stop development of matuzumab any further based on the clinical findings to date.
Subscribe to our email newsletter
Under the joint development program with Merck, matuzumab has been investigated in Phase II clinical trials in indications such as metastatic colorectal cancer (mCRC), gastric cancer, and non-small cell lung cancer (NSCLC), where it did not meet its predefined clinical endpoints of activity.
Discovered by Merck, matuzumab is a recombinant, humanized, monoclonal antibody (MAb) against the human EGFR (epidermal growth factor receptor), which is associated in the development and progression of a number of human solid tumors.